322 related articles for article (PubMed ID: 21062401)
1. First-trimester markers of aneuploidy in women positive for HIV.
Savvidou MD; Samuel I; Syngelaki A; Poulton M; Nicolaides KH
BJOG; 2011 Jun; 118(7):844-8. PubMed ID: 21062401
[TBL] [Abstract][Full Text] [Related]
2. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
4. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
Savvidou MD; Syngelaki A; Muhaisen M; Emelyanenko E; Nicolaides KH
BJOG; 2012 Mar; 119(4):410-6. PubMed ID: 22324916
[TBL] [Abstract][Full Text] [Related]
5. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
[TBL] [Abstract][Full Text] [Related]
6. First and second trimester markers of fetal aneuploidy in pregnant women with HIV infection.
Spencer K
Fetal Diagn Ther; 2011; 29(2):135-8. PubMed ID: 20714121
[TBL] [Abstract][Full Text] [Related]
7. A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K; Cowans NJ; Spencer CE; Achillea N
Prenat Diagn; 2010 Oct; 30(10):937-40. PubMed ID: 20687123
[TBL] [Abstract][Full Text] [Related]
8. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH
Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies.
Giorgetti C; Vanden Meerschaut F; De Roo C; Saunier O; Quarello E; Hairion D; Penaranda G; Chabert-Orsini V; De Sutter P
Hum Reprod; 2013 Oct; 28(10):2636-42. PubMed ID: 23887070
[TBL] [Abstract][Full Text] [Related]
10. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
[TBL] [Abstract][Full Text] [Related]
11. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
13. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
[TBL] [Abstract][Full Text] [Related]
14. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
15. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
16. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
17. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
18. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
19. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
20. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
